Relmada Therapeutics (RLMD) Stock
Clinical stage biotech developing pain and brain treatments. Here's the price, business snapshot, and what's worth knowing about Relmada Therapeutics in July 2026.
Relmada Therapeutics Inc (RLMD) is a small-cap, clinical-stage biotechnology company developing treatments in the central nervous system and pain space. With a market capitalisation around $74m, it is primarily value-driven by clinical trial milestones, regulatory reviews and potential partnerships or licensing deals. For investors, key considerations include the binary nature of clinical outcomes, a likely need for additional financing to fund development, and limited commercial revenue at this stage. The share price can be highly volatile and sensitive to trial data, analysts’ updates and broader biotech sector moves. Researching trial designs, timelines, cash runway and management experience can help form a view. This summary is educational and not investment advice; biotech stocks can offer significant upside but also substantial risk and loss of capital. Ensure any decision aligns with your risk tolerance and consider diversified exposure rather than relying on a single clinical-stage name.
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend buying RELMADA's stock, expecting significant value increase in the future.
Financial Health
Relmada Therapeutics is performing well in cash flow and book value, indicating solid financial strength.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring RLMD
Beyond Opioids: The Race For New Painkillers
Vertex Pharmaceuticals has halted the development of its non-opioid painkiller, creating uncertainty but also a potential opening for competitors. This theme focuses on other pharmaceutical companies that could capture market share as they advance their own non-opioid treatments.
Published: 5 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Trial Milestones Matter
Clinical readouts and regulatory steps tend to drive price moves; positive data can boost prospects but results can also disappoint.
Binary Outcomes Risk
Development-stage outcomes are often binary — success or failure — creating high volatility. Consider diversification to manage risk.
Funding And Partnerships
Cash runway and strategic partnerships can alter the company’s path; watch financing announcements that may dilute shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
